sinc
discoveri
rna
interfer
rnai
phenomenon
rnaibas
therapi
present
huge
potenti
treatment
mani
diseas
includ
inflammatori
infecti
diseas
cancer
numer
report
describ
develop
small
interf
rna
sirna
deliveri
system
invivo
applic
small
number
sirnabas
therapi
current
clinic
develop
essenti
due
lack
effici
safe
sirna
deliveri
system
intraven
administr
howev
deliveri
sirna
local
inject
could
repres
attract
rout
administr
limit
issu
toxic
associ
system
inject
describ
differ
synthet
vector
develop
local
deliveri
sirna
variou
organ
rna
interfer
rnai
effici
process
posttranscript
gene
silenc
cell
induc
short
interf
rna
sirna
consist
doublestrand
ds
rna
nucleotid
sirna
exert
genesilenc
activ
target
mrna
highli
specif
manner
via
rnainduc
silenc
complex
risc
bind
cognat
mrna
mediat
degrad
discoveri
rnai
gener
much
enthusiasm
within
scientif
commun
fact
sirna
molecul
hold
great
promis
biolog
tool
novel
therapeut
agent
particularli
area
oncolog
infecti
diseas
sever
studi
sirna
shown
allow
specif
target
select
gene
without
common
advers
effect
lessspecif
drugbas
therapi
danger
viral
gene
therapi
develop
effici
rnaibas
therapeut
face
challeng
design
optim
sirna
molecul
suitabl
deliveri
system
abl
deliv
sirna
effici
safe
repeatedli
invivo
applic
concern
design
optim
rnai
molecul
two
strategi
usual
describ
first
consist
chemic
synthesi
small
doublestrand
rna
molecul
approxim
nucleotid
asymmetr
overhang
directli
taken
risc
complex
cytoplasm
convers
short
hairpin
rna
shrna
compos
small
rna
sequenc
tight
hairpinturn
structur
load
plasmid
vector
ensur
express
shrna
nucleu
shrna
cleav
dicer
complex
produc
small
interf
sirna
taken
risc
complex
thu
depend
type
rnai
molecul
use
specif
vector
develop
must
optim
depend
rout
administr
tissu
cell
type
express
target
gene
whether
shortor
longterm
effect
requir
achiev
effici
sirna
deliveri
system
must
condens
sirna
nanoparticl
b
protect
sirna
enzymat
degrad
c
facilit
cellular
intern
promot
endosom
escap
e
stimul
innat
immun
report
focu
deliveri
chemic
synthes
duplex
sirna
plasmidencod
shrna
nonvir
deliveri
system
repres
promis
method
effici
sirna
deliveri
non
viral
deliveri
system
consist
usual
lipid
polymer
peptid
molecul
report
differ
strategi
develop
effici
deliv
sirna
local
administr
use
non
viral
vector
includ
mucos
non
mucos
applic
choic
rout
administr
import
determin
effici
sirna
deliveri
direct
applic
onto
mucos
surfac
respiratori
gastro
intestin
vagin
epithelium
attract
altern
system
deliveri
inde
mucos
deliveri
noninvas
method
allow
drug
deliveri
directli
target
site
main
point
entri
numer
pathogen
mucos
rout
reduc
nucleas
degrad
nanoparticl
hepat
clearanc
seruminduc
aggreg
facilit
direct
contact
target
cell
nevertheless
major
hurdl
effici
mucos
deliveri
includ
presenc
mucu
line
mucos
surfac
tight
epitheli
cell
arrang
sweep
away
potenti
penetr
materi
use
apic
cilia
report
describ
effici
mucos
deliveri
nake
sirna
lung
larg
volum
signific
amount
sirna
necessari
obtain
good
deposit
sirna
mucos
surfac
recent
improv
made
mucos
sirna
deliveri
lead
effici
inhibit
target
gene
low
dose
sirna
tabl
develop
effici
therapi
use
rna
interfer
treatment
prevent
lung
diseas
repres
promis
approach
due
high
exposur
pollut
airway
suscept
numer
diseas
cancer
inflammatori
infecti
diseas
mani
diseas
could
treatabl
local
sirna
treatment
hurdl
need
consid
develop
effici
sirna
deliveri
system
airway
rel
access
local
administr
drug
therapi
barrier
need
overcom
effici
sirna
deliveri
complex
structur
lung
must
consid
care
major
respiratori
diseas
especi
infecti
diseas
local
lower
airway
thu
sirna
deliveri
system
need
travers
upper
airway
reach
target
alveolar
surfac
lower
airway
upper
airway
present
highli
branch
structur
high
mucocilliari
clearanc
presenc
mucu
prevent
entri
exogen
particl
lower
airway
reach
lower
airway
sirna
particl
size
hydrodynam
behavior
need
optim
behavior
particl
may
predict
aerodynam
diamet
inde
larger
particl
aerodynam
diamet
greater
mainli
depos
mouth
throat
upper
lung
tissu
rapidli
elimin
similarli
particl
smaller
directli
exhal
elimin
deposit
alveoli
clearanc
mechan
also
need
consid
care
lower
airway
pulmonari
macrophag
ingest
degrad
micro
particl
bigger
nm
smaller
particl
may
escap
macrophag
clearanc
use
nanoparticl
poli
lacticcoglycol
acid
plga
could
repres
suitabl
deliveri
method
lung
epithelium
cover
mucu
nasal
caviti
bronchiol
wherea
alveolar
epithelium
line
alveolar
fluid
compos
phospholipid
surfact
case
sirna
target
local
alveolar
epithelium
surfact
could
affect
effici
lipidbas
deliveri
system
thu
would
prefer
use
synthet
deliveri
system
polym
mucu
secret
modifi
physiolog
condit
depend
state
diseas
exampl
inflammatori
condit
lead
increas
mucu
secret
inhal
mannitol
osmot
agent
prior
sirna
deliveri
could
reduc
mucu
secret
sirna
reach
cell
interest
cross
cellular
membran
enter
cytoplasm
sirna
neg
charg
molecul
approxim
kda
henc
abl
alon
cross
cellular
barrier
case
nonvir
sirna
deliveri
system
endocytosi
major
cellular
uptak
pathway
involv
sirna
intern
particl
need
smaller
nm
sever
type
endocyt
pathway
known
import
lung
caveolarmedi
endocytos
case
intern
particl
enclos
caveosom
non
acid
particl
could
directli
reach
risc
complex
cytoplasm
practic
sirna
deliveri
lung
usual
achiev
inhal
intratrach
intranas
administr
due
eas
applic
intranas
administr
method
mostcommonli
use
sirna
deliveri
achiev
deliveri
inhal
sirna
need
formul
dri
powder
liquid
aerosol
case
formul
sirna
critic
step
lyophil
aerosol
sirna
could
affect
effici
deposit
lung
report
lam
et
al
differ
inhal
devic
use
metereddos
inhal
mdi
drypowd
inhal
dpi
nebul
mdi
sirna
dissolv
suspend
propel
commonli
use
ideal
system
sirna
deliveri
limit
biostabl
sirna
formul
dpi
present
promis
advantag
sirna
deliveri
sirna
inhal
cloud
particl
allow
improv
stabil
sirna
formul
altern
mdi
dpi
nebul
use
deliveri
larg
volum
case
import
ensur
protect
sirna
formul
inde
sirna
could
damag
sheer
forc
nebul
dri
process
thu
formul
vector
need
protect
sirna
degrad
date
studi
report
sirna
deliveri
inhal
method
due
complex
sirna
formul
requir
inhal
intratrach
intranas
administr
wide
use
lung
sirna
deliveri
due
suitabl
inject
intratrach
administr
ensur
optim
effici
sirna
deliveri
minim
drug
loss
remain
invas
nonphysiolog
procedur
consid
applic
clinic
trial
human
use
experiment
anim
studi
pulmonari
deliveri
often
achiev
instil
small
volum
suspens
trachea
mice
endotrach
intub
use
aerosol
devic
penn
centuri
microspray
case
liquid
dri
powder
insufl
enabl
precis
quantif
deliv
dose
tradit
procedur
intratrach
administr
requir
microsurgeri
order
insert
cathet
tracheal
ring
recent
altern
method
develop
requir
incis
tracheal
tract
rather
cathet
insert
trachea
via
mouth
trachea
remain
intact
method
still
howev
invas
non
physiolog
intranas
deliveri
effici
altern
intratrach
deliveri
easi
perform
requir
low
level
anesthesia
howev
contrari
human
mice
oblig
nasal
breather
extrapol
human
potenti
effici
sirna
deliveri
method
may
overestim
sever
studi
use
inhibit
report
gene
optim
develop
non
viral
sirna
deliveri
system
pulmonari
administr
major
studi
involv
inhibit
enhanc
green
fluoresc
protein
egfp
express
endogen
egfpexpress
mice
beyerl
et
al
report
use
polyethylenimin
pei
howard
report
use
chitosan
eguchi
report
use
peptid
transduct
domaindoubl
strand
rnabind
domain
ptddrbd
peptidesbas
deliveri
system
drbd
bind
sirna
high
avid
mask
sirna
neg
charg
allow
ptdmediat
cellular
uptak
see
detail
tabl
lung
subject
numer
diseas
involv
epitheli
cell
cystic
fibrosi
asthma
also
infect
mani
virus
respiratori
synciti
viru
rsv
sar
corona
viru
scv
influenza
viru
rnaibas
therapi
repres
promis
approach
treatment
diseas
mani
sirna
deliveri
strategi
develop
describ
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
common
caus
seriou
respiratori
infect
infant
young
children
rsv
infect
upper
lower
respiratori
tract
lead
croup
pneumonia
bronchiol
rsv
piv
infect
could
notabl
reduc
delet
p
protein
rsv
piv
may
implic
viral
replic
thu
bitko
et
al
report
lung
deliveri
sirna
target
p
protein
respiratori
synciti
viru
parainfluenza
viru
two
sirna
rsv
one
piv
select
vivo
studi
mice
administ
intranas
approxim
sirna
complex
transitko
reagent
polycationliposom
formul
miru
corpor
madison
unit
state
four
hour
later
mice
intranas
infect
rsv
piv
evalu
sirna
efficaci
assess
five
six
day
viral
infect
maximum
rsv
replic
lung
occur
time
viral
titer
reduc
approxim
mice
treat
rsv
piv
sirna
compar
untreat
mice
notabl
nake
sirna
also
abl
inhibit
pulmonari
viral
titer
furthermor
viru
inhibit
highli
specif
rsv
sirna
inhibit
piv
vice
versa
transitko
reagent
caus
discomfort
uninfect
mice
mice
coadminist
three
sirna
coinfect
rsv
piv
viral
titer
significantli
reduc
addit
bitko
et
al
also
evalu
whether
sirna
deliveri
associ
cur
effect
infect
well
establish
case
mice
administ
sirna
time
one
day
viral
infect
show
stabl
increas
bodi
weight
compar
uninfect
mice
administr
sirna
later
two
four
day
viral
infect
led
lesseffect
protect
rsv
result
decreas
mous
bodi
weight
late
increas
bodi
weight
altogeth
result
suggest
rsv
sirna
deliveri
lung
enabl
protect
cur
effect
rsv
replic
use
anoth
strategi
akinc
et
al
report
use
lipidoid
new
class
lipidlik
vector
deliveri
rsvsirna
intranas
administr
lipidoid
obtain
conjug
addit
alkylacryl
alkylacrylamid
primari
secondari
amin
mice
intranas
administ
lipidoidsrsv
sirna
formul
dose
approxim
sirna
four
hour
later
infect
plaqueform
unit
rsv
viru
titer
assess
day
infect
akinc
et
al
observ
sirna
formul
lipidoid
enabl
two
logreduct
viral
plaqu
number
compar
nake
sirna
enabl
one
logreduct
author
report
specif
sirna
deliveri
lung
gene
silenc
observ
liver
kidney
sever
acut
respiratori
syndrom
sar
newli
emerg
diseas
caus
sar
coronaviru
effici
vaccin
treatment
individu
infect
sar
viru
present
high
fever
follow
sever
clinic
symptom
acut
respiratori
syndrom
sever
studi
report
vitro
inhibit
scv
li
et
al
report
intranas
deliveri
antiscv
sirna
rhesu
macaqu
model
sar
first
evalu
vivo
activ
anti
scvsirna
two
sirna
target
scv
genom
spikeproteincod
region
respect
test
sirna
co
deliv
pciscluc
plasmid
contain
correspond
target
sequenc
luciferas
report
gene
plasmid
pciscluc
formul
solut
dextros
water
infasurf
solut
forest
laboratori
inc
new
york
unit
state
deliv
intratrach
administr
mice
infasurf
steril
organ
solvent
extract
calf
lung
lavag
compos
surfact
protein
b
c
twentyfour
hour
sirna
deliveri
codeliveri
sirna
pciscluc
plasmid
formul
solut
result
higher
level
report
gene
express
stronger
rnai
silenc
compar
sirna
plasmid
formul
infasurf
solut
experi
rhesu
macaqu
model
carri
use
solut
sirna
administ
intratrach
dose
formul
follow
prophylact
concurr
post
exposur
protocol
analysi
macaqu
bodi
temperatur
indic
sever
sar
symptom
effect
sirna
treatment
show
protocol
led
potent
suppress
sar
pathogenesi
moreov
author
observ
diminish
scv
viral
level
reduc
acut
diffus
alveolar
damag
sign
sirnainduc
toxic
influenza
viru
one
preval
infect
human
current
vaccin
prevent
ill
need
formul
everi
year
viral
antigen
elicit
neutral
antibodi
chang
render
previou
year
vaccin
ineffect
new
subtyp
mani
sirna
specif
conserv
region
influenza
viru
genom
design
test
abil
inhibit
influenza
viru
product
vitro
tompkin
et
al
report
effici
influenza
viru
inhibit
vivo
use
oligofectaminemedi
sirna
deliveri
lung
assess
effici
sirna
deliveri
mice
pretreat
nake
sirna
intraven
inject
follow
h
later
infect
influenza
viru
second
dose
sirna
formul
lipid
carrier
oligofectaminetm
charg
ratio
administ
intranas
two
differ
sirna
influenza
viru
protein
np
pa
test
alon
combin
day
post
challeng
anim
receiv
control
sirna
die
wherea
anim
receiv
either
antinp
antipa
sirna
present
respect
mortal
interest
anim
receiv
sirna
show
surviv
author
also
success
evalu
abil
np
pa
sirna
inhibit
replic
influenza
virus
influenza
subtyp
studi
demonstr
combin
hydrodynam
intraven
deliveri
sirna
intranas
deliveri
lead
signific
inhibit
viru
replic
tompkin
et
al
also
observ
intraven
administr
alon
provid
signific
protect
less
effici
suggest
intranas
deliveri
contribut
surviv
studi
involv
differ
sirna
formul
differ
sirna
target
clearli
shown
sirna
deliveri
lung
promis
viabl
approach
treatment
viral
infect
lung
cancer
one
mostfrequ
tumor
worldwid
regard
incid
mortal
rate
although
knowledg
field
lung
cancer
research
increas
median
surviv
time
primarili
noncur
tumor
still
less
month
xu
et
al
assess
potenc
sirna
formul
poli
ester
amin
deliveri
treatment
lung
cancer
protein
kinas
one
mostfrequ
hyperactiv
signal
pathway
cancer
notabl
lung
cancer
poli
esteramin
biodegrad
polym
high
transfect
effici
low
toxic
compar
polyethyleneimin
pei
sirna
formul
polyc
poli
ester
amin
poli
ester
amin
sirna
charg
ratio
administ
mous
model
urethaneinduc
lung
cancer
nose
inhal
system
mice
expos
twice
week
total
four
week
aerosol
noseonli
exposur
chamber
describ
tehrani
et
al
analys
express
tumor
growth
perform
end
protocol
vivo
studi
clearli
demonstr
anticanc
effect
sirna
lung
aerosol
inhal
show
protein
express
knockdown
lung
suffici
suppress
pulmonari
tumor
progress
mice
urethaneinduc
lung
cancer
mice
moreov
aerosol
deliveri
sirna
affect
protein
express
organ
rna
interfer
also
promis
strategi
inhibit
express
patholog
express
gene
notabl
inflammatori
patholog
chronic
obstruct
pulmonari
diseas
moscho
et
al
investig
knockdown
map
kinas
conjug
sirna
differ
nonvir
deliveri
vector
cholesterol
tat
peptid
deriv
transactiv
transcript
tat
human
immunodefici
viru
penetratin
peptid
map
kinas
known
implic
releas
multipl
proinflammatori
mediat
includ
tumor
necrosi
factor
interleukin
il
inhibit
map
kinas
could
promis
approach
treatment
inflammatori
diseas
rheumatoid
arthriti
crohn
diseas
psoriasi
intratrach
administr
approxim
sirna
conjug
either
tat
penetratin
cholesterol
mice
result
knockdown
map
kinas
express
h
observ
nake
sirna
nevertheless
increas
amount
sirna
lead
improv
mrna
express
knockdown
rather
improv
durat
knockdown
except
sirna
conjug
penetratin
tat
peptid
alon
also
abl
reduc
map
kinas
express
suggest
tat
peptid
modul
map
kinas
interest
tat
peptid
cholesterolconjug
sirna
elicit
innat
immun
respons
contrari
penetratinconjug
sirna
studi
suggest
conjug
sirna
cpp
cholesterol
may
extend
increas
sirna
knockdown
lung
compar
nake
sirna
moreov
cpp
tat
peptid
abl
suppress
unintend
immunostimul
recognit
tolllikereceptor
tlr
usual
observ
sirna
intern
endosom
studi
requir
character
mechan
action
cpp
gene
express
immun
activ
oral
sirna
deliveri
conveni
costeffect
mean
deliv
sirna
diseas
intestin
tissu
nevertheless
main
challeng
oral
sirna
deliveri
protect
sirna
degrad
gastrointestin
enzym
allow
cross
intestin
mucosa
cellular
barrier
studi
achiev
success
oral
sirna
deliveri
anim
model
inflammatori
bowel
diseas
sirna
usual
encapsul
within
biodegrad
particl
protect
degrad
target
cell
peyer
patch
inflam
tissu
inflammatori
bowel
diseas
crohn
diseas
ulcer
coliti
character
chronic
inflamm
gastrointestin
tract
mani
factor
may
involv
etiolog
these
phenotyp
includ
genet
predisposit
environment
immun
factor
convent
treatment
base
antiinflammatori
immunesuppress
drug
lack
efficaci
high
rate
recurr
altern
surgic
remov
inflam
tissu
involv
pain
numer
strain
everyday
life
patient
thu
reduct
inflammatori
phenotyp
use
sirnabas
therapi
could
promis
approach
nevertheless
requir
develop
effici
vector
oral
sirna
deliveri
aoudi
et
al
first
report
success
oral
sirna
deliveri
encapsul
sirna
biodegrad
particl
sirna
design
silenc
mitogenactiv
protein
kinas
kinas
kinas
kinas
express
encapsul
porou
particl
consist
shell
deriv
baker
yeast
gerp
seri
chemic
extract
particl
made
central
core
transfer
rna
coat
layer
cation
pei
sirna
place
layer
pei
electrostat
interact
sirnacontain
gerp
administ
oral
mice
daili
eight
day
aim
target
cell
present
peyer
patch
intestin
wall
order
reach
macrophag
sirna
could
modul
cytokin
express
oral
deliveri
gerp
load
approxim
ng
sirna
author
report
intern
sirnagerp
particl
macrophag
expect
follow
mark
inhibit
mrna
level
lung
spleen
liver
respect
compar
control
moreov
genesilenc
effect
persist
eight
day
last
oral
sirna
deliveri
unexpect
immun
stimul
respons
interest
oral
deliveri
gerp
particl
load
ng
sirna
lead
effici
inhibit
mrna
express
dose
five
time
less
dosag
usual
use
system
sirna
deliveri
similarli
order
target
inflam
intestin
tissu
wilson
et
al
develop
anoth
oral
sirna
deliveri
system
base
fact
diseas
intestin
tissu
character
high
level
reactiv
oxygen
speci
ro
produc
site
inflamm
thu
ro
could
use
specif
trigger
sirna
releas
fere
ulcer
coliti
first
complex
cation
lipid
dioleoyl
trimethylammonium
propan
dotap
coencapsul
tkn
sirnaload
tkn
diamet
nm
order
limit
non
specif
uptak
enterocyt
promot
interact
phagocyt
mice
given
oral
scrambl
sirna
approxim
sirna
five
daili
gavag
seven
day
author
report
mark
tenfold
decreas
colon
mrna
treat
mice
compar
control
mice
reduc
clinic
manifest
ulcer
coliti
moreov
formul
anoth
vector
plga
particl
lead
signific
decreas
colon
mrna
suggest
specif
tkn
inflam
tissu
import
factor
effici
sirna
deliveri
studi
clearli
emphas
import
vector
design
effici
sirna
deliveri
target
cell
inde
tkn
chemic
properti
requir
sirna
deliveri
inflam
intestin
tissu
time
kriegel
et
al
develop
polymer
microspherebas
deliveri
system
name
nimo
oral
sirna
deliveri
model
ulcer
coliti
previous
describ
wilson
et
al
nimo
deliveri
system
compris
bgelatin
nanoparticl
encapsul
sirna
entrap
poli
epsiloncaprolacton
microsphereform
nanoparticlesinmicrospher
oral
system
composit
nimo
promot
intestin
local
deliveri
gelatin
particl
enterocyt
epitheli
cell
degrad
poli
epsiloncaprolacton
matrix
lipas
intestin
tract
investig
effici
nimo
system
oral
deliveri
sirna
author
develop
murin
model
ulcer
coliti
mice
receiv
oral
anti
particl
approxim
sirna
day
begin
ulcer
coliti
induct
day
mrna
protein
level
lower
mice
treat
particl
compar
control
mice
threefold
decreas
day
studi
show
import
advanc
made
oral
sirna
deliveri
may
lead
signific
develop
therapeut
treatment
inflammatori
intestin
diseas
clinic
vagin
sirna
deliveri
hold
great
potenti
prevent
treatment
variou
viral
infect
respons
diseas
genit
herp
acquir
immun
defici
syndrom
cervic
cancer
advantag
vagin
administr
numer
method
noninvas
bypass
hepat
clearanc
provid
local
deliveri
directli
target
tissu
reduc
amount
therapeut
agent
requir
effici
gene
silenc
vagin
sirna
deliveri
alreadi
describ
preclin
trial
treatment
herp
simplex
viru
hsv
method
remain
challeng
sirna
molecul
cross
mucos
barrier
taken
cervicovagin
epitheli
cell
avoid
nucleas
degrad
consid
intravagin
sirna
deliveri
system
need
effect
safe
nonirrit
mucos
surfac
inflamm
vagin
tissu
render
permiss
infect
major
develop
system
base
liposom
carrier
pallis
et
al
show
fitclabel
sirna
formul
commerci
reagent
oligofectamin
deliv
intravagin
effici
taken
vagin
ectocerv
epithelium
moreov
sirnatarget
egfp
administ
intravagin
oligofectamin
egfpexpress
mice
gfp
express
reduc
three
day
later
effect
persist
least
nine
day
without
system
silenc
distant
organ
nevertheless
report
lipoplex
remain
toxic
unstabl
high
ionic
condit
lead
seriou
concern
regard
use
liposom
carrier
deliv
sirna
mucos
surfac
woodrow
et
al
develop
biodegrad
polym
nanoparticl
enabl
effici
sirna
deliveri
mucos
surfac
author
report
poli
lacticcoglycol
acid
plga
nanoparticl
biodegrad
biocompat
properti
could
formul
sirna
deliv
vagin
mucosa
lead
effici
gene
silenc
singl
administr
sirnaplga
nanoparticl
vagin
mucosa
produc
effect
sustain
gene
silenc
throughout
femal
reproduct
tract
least
day
order
effici
encapsul
sirna
author
chose
preencapsul
sirna
spermidin
act
counterion
follow
sirnaspermidin
encapsul
plga
nanoparticl
charg
ratio
np
ratio
load
effici
ng
sirna
per
milligram
plga
topic
administr
cervicovagin
tract
plga
nanoparticl
detect
vagin
canal
uterin
horn
intravagin
deliveri
sirna
target
enhanc
green
fluoresc
protein
egfp
formul
plga
transgen
gfp
mice
led
reduct
gfp
express
reproduct
tract
ten
day
post
administr
use
approxim
sirna
mice
receiv
sirna
formul
plga
show
earlier
inhibit
egfp
express
without
histolog
modif
vagin
epithelium
compar
mice
receiv
sirna
formul
commerci
liposom
lipofectamin
rnaimax
invitrogen
show
thicken
vagin
epithelium
presenc
neutrophil
thu
plga
nanoparticl
attract
carrier
vagin
sirna
deliveri
abl
penetr
deepli
tissu
silenc
gene
express
effici
use
singl
dose
sirna
nevertheless
import
note
two
studi
mice
pretreat
progesteron
deriv
sirna
deliveri
inde
wu
et
al
report
convent
lipoplex
oligofectamin
administ
intravagin
unabl
reach
vagin
epithelium
normal
physiolog
condit
physiolog
chang
vagin
tract
throughout
estru
cycl
consid
affect
deliveri
macromolecul
vagin
tissu
outer
layer
epitheli
cell
becom
cornifi
hyperkeratot
mice
estru
report
wu
et
al
wu
et
al
recent
investig
challeng
deliv
sirna
vagin
tissu
normal
physiolog
condit
without
progesteron
treatment
mimic
accur
human
vagin
tract
develop
novel
algin
scaffold
system
contain
mucoinert
pegyl
lipoplex
base
dotap
cholesterol
lipid
provid
sustain
vagin
presenc
lipoplex
facilit
deliveri
sirna
vagin
epithelium
pegyl
lipoplexentrap
algin
scaffold
pla
fabric
use
freezedri
method
use
pegyl
liposom
enabl
better
particl
stabil
mucu
algin
scaffold
facilit
retent
particl
vagin
caviti
follow
intravagin
administr
author
compar
effici
intravagin
sirna
deliveri
pla
system
cation
lipoplex
result
show
sixfold
increas
percentag
uptak
sirna
vagin
tissu
pla
system
compar
cation
lipoplex
assess
level
sirna
knockdown
mice
treat
lamin
acsirna
formul
pla
system
per
dose
two
dose
administ
intravagin
mous
two
consecut
day
twentyfour
hour
later
knockdown
lamin
ac
vagin
tissu
mice
receiv
lamin
ac
sirna
treatment
compar
control
mice
studi
first
demonstr
vagin
sirna
deliveri
use
biodegrad
scaffold
liposom
novel
system
promis
approach
vagin
sirna
deliveri
eas
administr
offer
vital
featur
rapid
clinic
develop
vagin
mucosa
one
main
entri
point
numer
viral
bacteri
pathogen
caus
infecti
inflammatori
diseas
herp
simplex
viru
infect
caus
signific
morbid
import
cofactor
transmiss
hiv
infect
sirna
basedtherapi
could
promis
treatment
diseas
durabl
rnaibas
virucid
requir
administr
sexual
intercours
limit
problem
complianc
usual
encount
use
classic
microbicid
investig
abil
sirna
protect
mice
viru
pallis
et
al
pretreat
mice
progesteron
deriv
arrest
mice
diestrou
phase
estrou
cycl
may
facilit
epitheli
penetr
mice
infect
lethal
dose
viru
treat
sirna
formul
commerci
lipid
two
hour
four
hour
viral
infect
two
sirna
test
target
differ
essenti
viral
protein
dnabind
protein
envelop
glycoprotein
b
result
show
mice
treat
pmol
approxim
sirna
die
compar
control
group
day
viral
infect
analysi
diseas
sever
show
robust
protect
infect
sirnatr
mice
interest
mice
treat
sirna
less
protect
surviv
analysi
vagin
mucosa
sirnatr
mice
day
show
intact
epithelium
apoptot
bodi
compar
control
mice
show
denud
mucos
epithelium
high
level
inflammatori
cell
second
studi
author
investig
effect
sirna
treatment
post
infect
case
sirna
administ
alon
mixtur
three
six
hour
viral
infect
mice
receiv
one
sirna
present
surviv
advantag
compar
control
mice
interestingli
mice
receiv
mixtur
sirna
surviv
show
postexposur
treatment
could
also
effect
also
import
note
sirna
treatment
elicit
immun
respons
inflammatori
infiltr
nevertheless
wu
et
al
show
lipid
reagent
facilit
viral
infect
elicit
slight
inflamm
may
suffici
enhanc
viral
uptak
wu
et
al
investig
improv
durabl
protect
optim
deliveri
system
mous
model
herp
simplex
viru
develop
cholesterolconjug
sirna
singl
phosphothior
linkag
protect
sirna
degrad
genit
fluid
rnase
identifi
cell
surfac
receptor
receptor
possibl
target
rnaibas
therapi
case
assess
effici
cholsirna
conjug
vagin
deliveri
mice
pretreat
progesteron
deriv
previous
describ
challeng
mice
receiv
two
time
approxim
conjug
cholesterol
effici
protect
infect
sirna
administ
prior
infect
seven
day
prior
infect
author
report
combin
sirna
led
uniform
signific
protect
irrespect
time
sirna
administr
hsv
infect
moreov
intravagin
administr
cholsirna
induc
interferon
inflammatori
respons
thu
use
cholesterolconjug
sirna
seem
improv
protect
viral
infect
cholesterol
elicit
immun
respons
altogeth
result
studi
present
great
promis
prevent
andor
treatment
sexual
transmit
viral
infect
much
work
requir
optim
sirna
silenc
effici
develop
deliveri
system
suitabl
improv
vagin
retent
without
pretreat
vagin
caviti
order
suitabl
clinic
applic
human
intraves
sirna
deliveri
promis
approach
compar
system
deliveri
inde
intraves
sirna
deliveri
seem
achiev
similar
effect
system
deliveri
lower
dose
sirna
complex
moreov
procedur
transurethr
administr
quit
simpl
repeat
clinic
although
administr
murin
bladder
rather
difficult
describ
nogawa
et
al
mice
bladder
catheter
formul
administ
pursestr
sutur
place
around
urethra
occlud
four
hour
sutur
remov
mice
recommenc
spontan
void
major
bladder
cancer
diagnos
made
earli
stage
diseas
case
recur
advanc
stage
form
invas
cancer
case
standard
treatment
cystectomi
numer
undesir
side
effect
urinari
dysfunct
develop
noninvas
treatment
preserv
bladder
thu
desir
way
sirnabas
therapi
promis
tool
treatment
bladder
cancer
nogawa
et
al
first
report
intraves
deliveri
sirna
investig
intraves
deliveri
antipololik
sirna
treatment
bladder
cancer
protein
regul
mitot
progress
mammalian
cell
report
express
usual
associ
develop
numer
human
tumor
particular
bladder
cancer
nogawa
et
al
formul
sirna
cation
liposom
contain
egg
phosphatidylcholin
formul
administ
intraves
orthotop
bladder
cancer
mous
model
mice
administ
tumor
cell
day
transurethr
treatment
sirna
perform
five
time
day
five
nine
mice
receiv
sirna
sirna
success
deliv
tumor
lead
weak
express
associ
fewer
cancer
cell
observ
sirnatr
mice
compar
control
mice
moreov
treat
mice
show
total
erad
cancer
cell
without
advers
effect
indic
sirna
promis
tool
treatment
bladder
cancer
studi
first
demonstr
inbibit
cancer
growth
murin
bladder
intraves
sirnacation
liposom
deliveri
describ
section
local
non
viral
sirna
deliveri
strategi
concern
mucos
surfac
includ
intracerebr
intraocular
intratumor
sirna
deliveri
see
tabl
ii
numer
gene
express
brain
central
nervou
system
cn
identifi
potenti
target
treatment
neurolog
psychiatr
patholog
huntington
alzheim
diseas
sirna
wide
use
investig
gene
function
neuron
cultur
develop
vivo
sirna
deliveri
system
brain
impair
exist
bloodbrain
barrier
specif
metabol
brain
take
factor
account
report
describ
develop
sirna
deliveri
system
optim
treatment
cerebr
patholog
hassani
et
al
abl
knockdown
report
gene
express
new
born
mous
brain
use
jetsitmlipidbas
deliveri
system
follow
intracerebroventricular
inject
use
pg
sirna
formul
jetsi
tm
express
luciferas
report
gene
reduc
h
postdeliveri
brain
develop
cardoso
et
al
develop
cationicbas
sirna
deliveri
system
enhanc
sirna
deliveri
neuron
intrastriat
inject
sirna
formul
dotap
cholesterol
liposom
function
transferin
tflipoplex
ipsilater
hemispher
mous
brain
enabl
inhibit
luciferas
express
striatum
endogenouslyluciferaseexpress
mice
taken
togeth
studi
suggest
local
deliveri
sirna
cn
feasibl
option
target
cnsbase
diseas
base
preliminari
studi
author
assess
abil
rnaibas
therapi
treat
neurolog
diseas
huntington
alzheim
diseas
huntington
diseas
hd
neurodegen
diseas
character
loss
brain
neuron
caus
expans
cag
repeat
huntingtin
htt
gene
inhibit
hintingtin
express
brain
neuron
reduc
sever
diseas
effici
sirna
target
htt
protein
identifi
vitro
wang
et
al
deliv
httsirna
brain
neuron
newborn
hd
mice
assess
benefit
sirna
hd
sever
formul
compris
httsirna
cation
lipid
lipofectamin
administ
newborn
mice
later
ventricl
report
shen
et
al
ninetysix
hour
sirna
deliveri
bodi
weight
loss
hd
mice
treat
httsirna
slow
compar
control
mice
lifespan
treat
mice
extend
two
week
moreov
sirna
treatment
reestablish
motor
function
delay
onset
reduc
frequenc
feetclasp
behavior
hd
mice
measur
htt
mrna
residu
express
level
author
report
htt
mrna
maintain
one
week
stratium
remot
area
ventricl
cortex
studi
first
report
success
use
sirnabas
therapi
hd
mous
model
use
one
intraventricular
inject
birth
howev
investig
requir
improv
biodistribut
deliv
sirna
develop
lessinvas
deliveri
method
altern
use
thecation
lipid
lipofectamin
could
toxic
neuron
cell
difiglia
et
al
report
use
cholesterolconjug
sirna
target
htt
new
virusmedi
transgen
model
hd
adult
mice
singl
administr
cholesterolconjugatedhttsirna
right
striatum
mice
suffici
inhibit
htt
mrna
express
striatum
least
three
day
lead
amelior
multipl
neuropatholog
featur
aberr
motor
featur
three
week
contrari
find
wang
et
al
difiglia
demonstr
sirna
treatment
enabl
therapeut
benefit
adult
mous
model
hd
singl
puls
sirna
deliveri
similarli
mous
model
alzheim
diseas
uno
et
al
report
effici
deliveri
sirna
brain
combin
high
densiti
lipoprotein
hdl
sirna
tocsirna
author
identifi
target
gene
encod
bsite
amyloid
precursor
proteincleav
impli
alzheim
diseas
patholog
assess
effici
tocsirnahdl
vivo
particl
administ
mous
brain
direct
intracerebroventricular
infus
osmot
pump
describ
thakker
et
al
compar
free
tocsirna
continu
inject
approxim
tocsirna
hdl
particl
seven
day
led
broader
intens
transduct
tocsirna
signific
reduct
target
mrna
express
hippocamp
pariet
cortex
tocsirnahdl
compar
free
tocsirna
pariet
cortex
thu
tocsirnahdl
particl
enabl
effici
genesilenc
brain
use
lower
amount
sirna
previou
studi
improv
genesilenc
effici
could
explain
better
uptak
sirna
tocsirnahdl
vector
system
may
util
physiolog
lipid
metabol
inde
may
transfer
glial
cell
neuron
via
receptormedi
pathway
hdllike
particl
report
difiglia
et
al
next
challeng
improv
safe
deliveri
sirna
brain
maxim
target
specif
autosom
neurodegen
diseas
hd
requir
treatment
year
adjust
discontinu
side
effect
aris
henc
modular
action
sirna
therapeut
promis
tool
treatment
diseas
use
differ
approach
tan
et
al
use
branch
pei
intrathec
sirna
deliveri
rat
model
deliveri
sirna
target
nmethyldaspart
receptor
subunit
protein
formul
branch
pei
intrathec
inject
subarachnoid
led
inhibit
protein
express
modul
pain
use
sirnabas
therapi
promis
treatment
ocular
diseas
cytomegaloviru
infect
agerel
macular
degener
amd
howev
administr
method
posterior
segment
eye
invas
harm
repeat
inde
case
target
site
sirna
treatment
posterior
segment
eye
sirna
abl
penetr
alon
cornea
deliv
intravitr
moreov
sirna
short
intravitr
halflif
impli
repeat
administr
obtain
effici
modul
target
gene
express
increas
risk
endophthalm
retin
detach
thu
optim
vector
develop
ensur
cellular
penetr
protect
degrad
longterm
deliveri
sirnabas
therapi
current
test
clinic
trial
notabl
treatment
amd
vegf
endotheli
growth
factor
cell
specif
mitogen
implic
modul
angiogen
process
notabl
amd
diseas
mani
studi
shown
success
intraocular
deliveri
sirna
target
vegf
vegf
receptor
lead
inhibit
neovascular
sever
valid
preclin
model
murata
et
al
report
use
subconjunctiv
administr
vegf
sirna
formul
lipofectamin
express
vegf
significantli
inhibit
induc
corneal
model
angiogenesi
without
damag
conjunctiva
howev
kleinman
et
al
recent
shown
inhibit
vegf
express
model
use
nake
sirna
due
sequencespecif
rna
interfer
mechan
rather
intrins
properti
sirna
molecul
mediat
receptor
inde
author
demonstr
longer
dsrna
display
antiangiogen
properti
via
receptor
activ
mani
tumor
model
develop
studi
variou
cancer
includ
prostat
brain
pancreat
cancer
sirnabas
therapeut
present
promis
approach
treatment
diseas
describ
report
numer
studi
studi
shown
system
deliveri
sirna
local
deliveri
promis
altern
increas
target
specif
reduc
offtarget
effect
report
variou
intratumor
deliveri
system
develop
case
prostat
cancer
frequent
diagnos
cancer
men
usa
tumor
metastasi
usual
appear
bone
skelet
metastas
identifi
autopsi
patient
die
diseas
bisanz
et
al
report
intratumor
sirna
deliveri
model
human
cancer
prostat
cell
induc
tibia
one
microgram
antiintegrin
alphav
sirna
formul
cation
liposomebas
formul
compos
dipalmitoylethylphosphocholin
dioleoylphosphoethan
olamin
dipalmitoylphosphoethanoamin
polyethyleneglycol
author
report
reduct
integrin
alphav
express
reduct
tumor
growth
improv
target
sirna
deliveri
consid
tumor
cell
high
folat
receptor
express
yoshizawa
report
intratumor
sirna
deliveri
use
folatelink
lipidbas
nanoparticl
model
human
oral
epidermoid
carcinoma
cell
kb
xenograft
anoth
strategi
consist
use
peibas
deliveri
system
base
tumor
model
brain
cancer
specif
mous
model
glioblastoma
cell
grow
intracrani
grzelinski
et
al
demonstr
intratumor
administr
sirna
target
growth
factor
pleiotrophin
complex
pei
led
inhibit
xenograft
growth
way
peibas
deliveri
system
wide
use
intratumor
sirna
deliveri
report
kim
interestingli
han
et
al
develop
chitosanbas
hydrogel
display
temperaturedepend
liquidsolid
phase
transit
could
directli
inject
tumor
site
gradual
degrad
enzym
tumor
site
complet
releas
sirna
anoth
approach
crombez
et
al
use
nmethylpurinedna
glycosylas
mpg
peptidebas
deliveri
vector
intratumor
sirna
deliveri
differ
mous
tumor
model
intratumor
administr
sirna
formul
peptid
carrier
mpg
function
cholesterol
promot
effici
deliveri
sirna
reduc
tumor
growth
differ
mous
tumor
model
numer
studi
achiev
develop
local
sirna
deliveri
system
use
non
viral
vector
deliveri
system
test
clinic
trial
tabl
iii
notabl
case
sirna
therapeut
term
chemic
modifi
sirna
target
vegf
receptor
enter
phase
ii
trial
seemingli
prove
clinic
signific
improv
visual
acuiti
seriou
advers
event
doselimit
toxic
relev
subset
patient
report
variou
synthet
vector
local
sirna
deliveri
develop
improv
effici
gene
silenc
howev
synthet
vector
use
local
sirna
deliveri
essenti
optim
vitro
applic
includ
oligofectamin
transitko
chitosan
plga
deliveri
system
moreov
commerci
reagent
without
known
composit
would
impair
optim
clinic
develop
concern
mucos
sirna
deliveri
lipid
base
deliveri
vector
ideal
vector
due
possibl
interact
surfact
notabl
lung
case
lung
sirna
deliveri
polymerbas
deliveri
system
chitosan
conjug
deliveri
system
would
prefer
way
vagin
administr
sirna
requir
use
polymerbas
deliveri
system
plga
nanoparticl
biodegrad
biocompat
use
pegyl
lipoplex
also
seem
effici
vagin
sirna
deliveri
convers
nonmucos
sirna
deliveri
requir
develop
sophist
sirna
deliveri
system
inde
effici
sirna
deliveri
central
nervou
system
achiev
use
commerci
avail
vector
lipofectamin
jetsi
conjug
sirna
altern
method
nevertheless
intracerebr
administr
sirna
highli
invas
method
must
improv
way
effici
intratumor
sirna
deliveri
achiev
use
polymerbas
deliveri
system
pei
chitosan
system
previous
use
gene
deliveri
need
optim
order
reduc
toxic
improv
effici
way
studi
develop
synthet
sirna
deliveri
especi
design
sirna
deliveri
aminoglycosid
deriv
way
gerp
particl
deriv
baker
yeast
nimo
particl
compos
bgelatin
nanoparticl
specif
design
oral
sirna
deliveri
order
avoid
degrad
sirna
gastrointestin
enzym
promot
sirna
internaliza
local
sirna
deliveri
nonvir
vector
tion
target
cell
review
clearli
show
sirna
deliveri
system
must
optim
depend
rout
administr
consid
specif
system
major
challeng
remain
improv
safeti
current
clearli
impair
clinic
develop
sirna
deliveri
system
moreov
remain
difficult
translat
result
obtain
anim
model
human
anatom
physiolog
differ
human
anim
rout
administr
use
experiment
anim
also
gener
suitabl
futur
administr
treatment
human
